SEC Form 3 · accession 0001231919-26-001226
ADARx Pharmaceuticals, Inc. · ADRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
LAV Biosciences Fund V, L.P.
10% Owner
LAV Fund VI Opportunities, L.P.
10% Owner
LAV Fund VI, L.P.
10% Owner
Period of report
Sep 24, 2026
Accepted (ET)
Sep 24, 2026 · 6:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001802369
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF2,F1 | — | holding | — | — | — | — | — | Common Stock | 8,908,775 | — | D |
| Series B Preferred StockF2,F1 | — | holding | — | — | — | — | — | Common Stock | 1,667,469 | — | D |
| Series B-1 Preferred StockF2,F1 | — | holding | — | — | — | — | — | Common Stock | 513,067 | — | D |
| Series C Preferred StockF2,F1 | — | holding | — | — | — | — | — | Common Stock | 153,868 | — | D |
| Series C Preferred StockF3,F1 | — | holding | — | — | — | — | — | Common Stock | 307,738 | — | I |
| Series C Preferred StockF4,F1 | — | holding | — | — | — | — | — | Common Stock | 307,738 | — | I |
Explanation of responses
- F1Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") will automatically convert on a 1-for-1.1717 reverse stock split basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.
- F2LAV GP V, L.P. is the general partner of LAV Biosciences Fund V, L.P. ("LAV Biosciences"). LAV Corporate V GP, Ltd. is the general partner of LAV GP V, L.P. Dr. Yi Shi is the managing partner of LAV Corporate V GP, Ltd. By virtue of these relationships, LAV GP V, L.P., LAV Corporate V GP, Ltd. and Dr. Yi Shi may be deemed to have voting and investment power of the shares held by LAV Biosciences.
- F3Shares are held by LAV Fund VI, L.P. ("LAV Fund VI"). LAV GP VI, L.P. ("LAV GP VI") is the general partner of LAV Fund VI and LAV Corporate VI GP, Ltd. ("LAV Corporate VI GP") is the general partner of LAV GP VI., L.P. Dr. Yi Shi is the managing partner of LAV Corporate VI GP, Ltd. By virtue of these relationships, LAV GP VI, L.P., LAV Corporate VI GP, Ltd. and Dr. Yi Shi may be deemed to have voting and investment power of the shares held by LAV Fund VI, L.P.
- F4Shares are held by LAV Fund VI Opportunities, L.P. ("LAV Fund VI Opportunities"). LAV GP VI Opportunities, L.P. ("LAV GP VI Opportunities") is the general partner of LAV Fund VI Opportunities, L.P. and LAV Corporate VI GP Opportunities, Ltd. ("LAV Corporate VI GP") is the general partner of LAV GP VI Opportunities, L.P. Dr. Yi Shi is the managing partner of LAV Corporate VI GP Opportunities, Ltd. By virtue of these relationships, LAV GP VI Opportunities, L.P., LAV Corporate VI GP Opportunities, Ltd., and Dr. Yi Shi may be deemed to have voting and investment power of the shares held by LAV Fund VI Opportunities., L.P.